Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Advances in the Diagnosis and Treatment of Solid and Hematologic...
share announcement

Advances in the Diagnosis and Treatment of Solid and Hematologic Neoplasms

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 20 May 2025 | Viewed by 2068

Special Issue Editors

Dr. Andrea Palicelli

E-Mail Website
Guest Editor
Pathology Unit, Azienda USL–IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy
Interests: surgical pathology; gynecological pathology; uropathology; molecular pathology
Special Issues, Collections and Topics in MDPI journals
Dr. Aleksandra Asaturova

E-Mail Website
Guest Editor
National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after Academician V.I. Kulakov of the Ministry of Health of Russia, Bldg. 4, Oparina Street, 117513 Moscow, Russia
Interests: gynecological pathology and cytology; molecular and computational pathology; pathology informatics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue invites contributions that explore innovative approaches and advancements in the diagnosis and treatment of solid and hematologic neoplasms. We encourage original research articles, experimental studies, and comprehensive reviews that delve into clinical practices, radiological imaging techniques, histopathological assessments, and molecular diagnostics. Additionally, we welcome papers that address the latest developments in surgical, oncological, and radiotherapeutic interventions, with a focus on improving patient outcomes. Manuscripts that highlight multidisciplinary strategies, novel therapeutic modalities, and personalized medicine are particularly encouraged. Through this collaborative platform, we aim to foster a deeper understanding of neoplastic diseases and their management, ultimately enhancing the care provided to patients.

We hope that your participation will contribute to this attractive and interesting Special Issue. 

Dr. Andrea Palicelli
Dr. Aleksandra Asaturova
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • pathology
  • molecular analysis
  • diagnosis
  • treatment
  • surgery
  • radiotherapy
  • oncology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 12432 KiB  
Article
OVsignGenes: A Gene Expression-Based Neural Network Model Estimated Molecular Subtype of High-Grade Serous Ovarian Carcinoma
by Anastasiya Kobelyatskaya, Anna Tregubova, Andrea Palicelli, Alina Badlaeva and Aleksandra Asaturova
Cancers 2024, 16(23), 3951; https://doi.org/10.3390/cancers16233951 - 25 Nov 2024
Viewed by 949
Abstract
Background/Objectives: High-grade serous carcinomas (HGSCs) are highly heterogeneous tumors, both among patients and within a single tumor. Differences in molecular mechanisms significantly describe this heterogeneity. Four molecular subtypes have been previously described by the Cancer Genome Atlas Consortium: differentiated, immunoreactive, mesenchymal, and proliferative. [...] Read more.
Background/Objectives: High-grade serous carcinomas (HGSCs) are highly heterogeneous tumors, both among patients and within a single tumor. Differences in molecular mechanisms significantly describe this heterogeneity. Four molecular subtypes have been previously described by the Cancer Genome Atlas Consortium: differentiated, immunoreactive, mesenchymal, and proliferative. These subtypes may have varying degrees of progression, relapse-free survival, and overall survival, as well as response to therapy. The precise determination of these subtypes is certainly necessary both for diagnosis and future development of targeted therapies within personalized medicine. Methods: In this study, we analyzed gene expression data based on bulk RNA-seq, scRNA-seq, and spatial transcriptomic data from six cohorts (totaling 535 samples, including 60 single-cell samples). Differential expression analysis was performed using the edgeR package. The KEGG database and GSVA package were used for pathways enrichment analysis. As a predictive model, a deep neural network was created using the keras and tensorflow libraries. Results: We identified 357 differentially expressed genes among the four subtypes: 96 differentiated, 33 immunoreactive, 91 mesenchymal, and 137 proliferative. Based on these, we created OVsignGenes, a neural network model resistant to the effects of platform (test dataset AUC = 0.969). We then ran data from five more cohorts through our model, including scRNA-seq and spatial transcriptomics. Conclusions: Because the differentiated subtype is located at the intersection of the other three subtypes based on PCA and does not have a unique profile of differentially expressed genes or enriched pathways, it can be considered an initiating subtype of tumor that will develop into one of the three other subtypes. Full article
(This article belongs to the Special Issue Advances in the Diagnosis and Treatment of Solid and Hematologic Neoplasms)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop